Steven C. Baughman

Steven C. Baughman is a founding partner of the patent litigation boutique Groombridge, Wu, Baughman & Stone LLP, which he co-founded in November 2022 after leaving Paul, Weiss, Rifkind, Wharton & Garrison LLP. His practice is heavily focused on post-grant proceedings before the Patent Trial and Appeal Board (PTAB), where he is considered a leading national practitioner. Baughman's work spans a wide array of technologies, including pharmaceuticals, biologics, medical devices, semiconductors, and software. He has represented major technology and life sciences companies such as Novo Nordisk, Apple, Amgen, and Samsung.

The provided data shows Baughman representing the defendant in his tracked case, Qomplx LLC v. Palo Alto Networks, Inc, a software patent dispute filed in 2025. His broader practice history demonstrates extensive work on behalf of both patent challengers and patent owners in high-stakes disputes. He has been counsel of record in more than 200 inter partes review (IPR), post-grant review (PGR), and covered business method (CBM) proceedings. For a period, he achieved a 47-0 record in final written decisions for petitioners while also successfully defending key patents for owners.

Baughman is a preeminent figure in PTAB practice. He was involved in several of the first-ever proceedings at the board in 2012, including the first to reach a final decision. He helped establish the PTAB Bar Association and served as its president from 2020 to 2021. A recent notable success includes his representation of Novo Nordisk, defeating IPR challenges to patents covering the blockbuster drugs Ozempic® and Wegovy®.

Mr. Baughman earned his B.S.E. in Electrical Engineering from Princeton University and his J.D. from Harvard Law School.